이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Effect of Whirlpool Therapy Combined With Botulinum Toxin in Children With Cerebral Palsy

2026년 7월 6일 업데이트: AYŞENUR GENÇER ÖZTÜRK, Ankara Etlik City Hospital

Investigation of the Effects of Combining Whirlpool Therapy With Botulinum Toxin Treatment on Spasticity, Gait, and Motivation in Children With Cerebral Palsy

This study aims to investigate the effects of adding whirlpool therapy to standard rehabilitation in children with cerebral palsy who recently received botulinum toxin-A injections. Participants will be divided into two groups: one group will receive standard physiotherapy, while the other group will receive physiotherapy combined with whirlpool therapy. The effects of these interventions on spasticity, gait function, and motivation will be evaluated over a 12-week follow-up period.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

This study was designed as a prospective, randomized, single-blind (assessor-blinded), parallel-group controlled clinical trial investigating the effects of combining whirlpool therapy with botulinum toxin type A (BoNT-A)-assisted rehabilitation on spasticity, gait, and motivation in children with hemiplegic cerebral palsy.

A total of 81 patients with hemiplegic cerebral palsy who had received botulinum toxin type A (BoNT-A) injections to selected lower extremity muscles within the previous week were initially evaluated. After applying the inclusion and exclusion criteria, 43 participants were enrolled in the study, and 38 patients were excluded. All botulinum toxin injections were performed using onabotulinumtoxinA by an experienced physiatrist with more than five years of clinical experience. Injection planning was individualized according to body weight, severity of spasticity, and targeted muscle groups.

Participants were randomly assigned in a 1:1 ratio to two groups (22 in the intervention group and 21 in the control group). Randomization was performed using a computer-generated random sequence by an independent researcher who was not involved in treatment or assessment. Allocation concealment was ensured using sequentially numbered, opaque, sealed envelopes. The study was conducted as a single-blind trial in which the outcome assessors were blinded to group allocation, while participants and therapists were not blinded because of the nature of the intervention.

Both groups received a conventional rehabilitation program for 4 weeks, 5 days per week, 1 hour per day. The program included range of motion (ROM) exercises for the upper and lower extremities, stretching and strengthening exercises, balance and coordination training, endurance exercises, and ambulation training, all delivered under physiotherapist supervision according to a standardized protocol.

In addition to conventional rehabilitation, the intervention group received whirlpool therapy three times per week for 4 weeks, with each session lasting 20 minutes, for a total of 12 sessions. All whirlpool therapy sessions were conducted under physiotherapist supervision.

Outcome measures were assessed at three time points: baseline (T0, week 0, pre-treatment), post-treatment (T1, week 4), and follow-up (T2, week 12). Spasticity was evaluated using the Modified Ashworth Scale (MAS) and the Modified Tardieu Scale (MTS). Functional mobility and standing/walking abilities were assessed using the Gross Motor Function Measure-88 (GMFM-88) dimensions D and E. Motivation was evaluated using the Pediatric Motivation Scale. Gait kinematics, including joint range of motion and peak flexion and extension angles of the hip, knee, and ankle, were analyzed using the DIERS 4D Motion Lab system. Functional walking performance was assessed using the 10-Meter Walk Test (10MWT).

연구 유형

중재적

등록 (실제)

43

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Ankara
      • Ankara, Ankara, 터키 (Türkiye), 06010
        • Ankara Etlik City Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  • Diagnosis of hemiplegic cerebral palsy
  • Age between 3 and 10 years
  • Gross Motor Function Classification System (GMFCS) levels I-II
  • Sufficient cognitive level to follow instructions
  • Ability to walk at least 10 meters with an orthosis and/or walking aid
  • Receipt of botulinum toxin injection to the lower extremity within the past week
  • Ability to walk independently for 1 minute without orthosis or assistive device

Exclusion Criteria:

  • Uncontrolled epilepsy
  • Urinary incontinence
  • Presence of lower extremity contractures
  • History of previous orthopedic surgery
  • Presence of hip subluxation
  • Ataxic or dyskinetic cerebral palsy
  • History of any botulinum toxin injection within the 6 months prior to the current 1-week post-injection period
  • Inability to cooperate during clinical assessments

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Botulinum Toxin + Conventional Physiotherapy + Whirlpool Therapy
Patients receiving 4 weeks of conventional physical therapy combined with whirlpool therapy (20 minutes per session, 3 times per week).
Standard rehabilitation program including range of motion exercises, stretching, strengthening, balance, coordination, endurance, and gait training, 5 days per week for 4 weeks under physiotherapist supervision.
Whirlpool therapy administered 3 times per week for 4 weeks, 20 minutes per session (total 12 sessions), in addition to conventional rehabilitation.
활성 비교기: Botulinum Toxin + Conventional Physiotherapy
Patients receiving 4 weeks of conventional physical therapy alone.
Standard rehabilitation program including range of motion exercises, stretching, strengthening, balance, coordination, endurance, and gait training, 5 days per week for 4 weeks under physiotherapist supervision.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Gross Motor Function Measure-88 (GMFM-88) - Dimension E (Walking, Running and Jumping)
기간: Baseline (Week 0), Week 4 (post-treatment), Week 12 (follow-up)
The primary outcome measure was the Gross Motor Function Measure-88 (GMFM-88) Dimension E, which evaluates walking, running, and jumping abilities in children with hemiplegic cerebral palsy. Each item is scored on a 4-point scale (0-3), and raw scores are converted to percentage values (0-100). Dimension E consists of 24 items, with a maximum raw score of 72 points.
Baseline (Week 0), Week 4 (post-treatment), Week 12 (follow-up)

2차 결과 측정

결과 측정
측정값 설명
기간
Modified Ashworth Scale (MAS)
기간: Week 0, Week 4, Week 12
Spasticity was assessed using the MAS. Scores were recorded for the hamstring, gastrocnemius, and adductor muscles of the affected side. The MAS is a 6-point ordinal scale (0, 1, 1+, 2, 3, and 4) used to assess resistance to passive movement, with higher scores indicating greater muscle spasticity.
Week 0, Week 4, Week 12
Pediatric Motivation Scale
기간: Week 4, Week 12
Motivation was assessed using the Pediatric Motivation Scale (PMS), a validated self-report instrument designed to evaluate children's motivation toward rehabilitation. The scale consists of 21 items and includes six domains: effort-importance, interest-enjoyment, competence, relatedness, autonomy, and value-usefulness. The first 19 items are rated on a 6-point Likert scale ranging from 1 ("not at all true") to 6 ("very true"), while the remaining two items are open-ended questions. Total and domain scores are calculated from the Likert-scale items. Higher scores indicate greater motivation, stronger engagement in rehabilitation activities, and a higher degree of internally regulated motivation.
Week 4, Week 12
DIERS 4D Motion Analysis System
기간: Baseline (Week 0), Week 4, Week 12
Three-dimensional gait kinematics were assessed using the DIERS 4D motion analysis system. Maximum hip, knee, and ankle flexion and extension angles of the hemiparetic limb were recorded. Additionally, bilateral knee valgus and varus angles were measured during gait. All data were automatically stored in the system memory for further analysis.
Baseline (Week 0), Week 4, Week 12
10-Meter Walk Test (10MWT)
기간: Baseline (Week 0), Week 4, Week 12
Walking performance was assessed using the 10MWT. Participants walked a 10-meter straight path at their comfortable walking speed. Time was recorded in seconds, and gait speed (m/s) and cadence (steps/min) were calculated. Two trials were performed, and the best performance was recorded.
Baseline (Week 0), Week 4, Week 12
Gross Motor Function Measure-88 (GMFM-88) - Dimension D (Standing)
기간: Baseline (Week 0), Week 4, Week 12
The GMFM-88 Dimension D was used to assess standing ability in children with hemiplegic cerebral palsy. This domain consists of 13 items evaluating static and dynamic standing activities. Each item is scored on a 4-point scale (0-3), and raw scores are converted to percentage values (0-100) based on the maximum achievable score.
Baseline (Week 0), Week 4, Week 12
Modified Tardieu Scale (MTS)
기간: Week 0, Week 4, Week 12
Spasticity was assessed using the MTS for the hamstring and gastrocnemius muscles of the affected side. Passive movement was performed at V1 (slow velocity) and V3 (fast velocity). Muscle reaction quality, R1, R2, and R2-R1 values were recorded.
Week 0, Week 4, Week 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: DAMLA CANKURTARAN, MD, Ankara Etlik City Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 2월 1일

기본 완료 (실제)

2026년 5월 1일

연구 완료 (실제)

2026년 5월 31일

연구 등록 날짜

최초 제출

2026년 6월 13일

QC 기준을 충족하는 최초 제출

2026년 7월 6일

처음 게시됨 (실제)

2026년 7월 8일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 8일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 6일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • AEŞH-EK1-2025-046

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .